Supervisory authorities



Home > Directory > CHEMBIO

TOP Siden
PhD; Research Director, CNRS

Sorbonne Université,
4 Place Jussieu, 75252 Paris cedex 5

Couloir 33-43 4ème étage. case 229
Team Chembio

Tel:33(0)1 44 27 66 99


Research interests:

Bioorganometallic chemistry, organometallic anticancer agents, radiopharmaceuticals.

Current research:

Development of bioorganometallic chemistry. This topic encompasses exploration and exploitation of the unique properties of organometallic compounds to offer novel solutions to biochemical and biological problems. The principal areas addressed are:

  • Synthesis of biological substances complexed by transition metals.
  • Applications of transition metals in therapy and medical imaging.
  • Use of organometallics to combat plant diseases.

Recent results:

  • A new series of ferrocene compounds particularly active against MDA-MB-231 cancer cells (IC50 of 0.06 µM in the best case). They are characterized by the presence of a hydroxyl function on the ethyl group of ferrocifen (Molecules, 2014, 19, 10350-10369 and European patent no. EP13306480).

  • Research on the cellular targets of ferrocene derivatives. Synthesis of ferrocifen-SAHA hybrids. Study of the link between antiproliferative activity and inhibitory activity in histone deacetylase (HDAC). (Dalton Trans., 2013, 42, 15489-1551; Dalton Trans., 2014, 43, 817-830).

  • A novel series of ferrocene compounds (ferrocenophanes) with better antiproliferative activity than ferrocifen or ferocidiphenol against hormone independent MDA-MB-231 cancer cells. Examples are the derivative diamino ferrocenophane (IC50 = 0.05 µM, MedChemComm, 2010, 1, 149-151) ) and pinacol ferrocenophane (IC50 = 0.1 µM, Organometallics, 2012, 31, 5856-5866).

  • Synthesis and in vivo biodistribution study of a compound of 99mTc in the triarylethylene series. The compound accumulates in the ovaries and this uptake appears to be modulated by the estrogen receptor (J. Organomet. Chem., 2013, 699, 21-29).

  • Ferrocene derivatives are active against diseases of young olive plants (J. Plant Pathology, 2011, 93, 651-657)

Scientific career:

  • Studied at the University of Rennes
  • PhD from Rennes under the supervision of Dr. Gérard Jaouen and Professor René Dabard (1979).
  • Postdoctoral work at UCLA in the laboratory of Professor H. D. Kaesz.

Selected publications:

  1. Atypical McMurry Cross-Coupling Reactions Leading to a New Series of Potent Antiproliferative Compounds Bearing the Key [Ferrocenyl-Ene-Phenol] Motif. Pascal Pigeon, Meral Gôrmen, Konrad Kowalski, Helge Mûller-Bunz, Michael J. McGlinchey, Siden Top*, Gérard Jaouen*. Molecules, 2014, 19, 10350-10369.
  2. Oxidative Sequence of a Ruthenocene-Based Anticancer Drug Candidate in a Basic Environment. Hui Zhi Shirley Lee, Olivier Buriez,* Eric Labbé, Siden Top,* Pascal Pigeon, G. Jaouen, Christian Amatore,* Weng Kee Leong. Organometallics, 2014, 4940-4946.
  3. Efficient New Constructs against Triple Negative Breast Cancer Cells: Synthesis and Preliminary Biological Study of Ferrocifen-SAHA Hybrids and related species. José de Jesús Cázares-Marinero, Marion Lapierre, Vincent Cavaillès*, Rénette Saint-Fort, Anne Vessières, Siden Top*, Gérard Jaouen. Dalton Trans., 2013, 42, 15489-1551.
  4. Synthesis and antiproliferative evaluation of ferrocenyl and cymantrenyl triaryl butene on breast cancer cells. Biodistribution study of the corresponding technetium-99m tamoxifen conjugate. Tesnim Dallagi,* Mouldi Saidi, Anne Vessières, Michel Huché, Gérard Jaouen, Siden Top*. J. Organomet. Chem., 2013, 734, 69-77.
  5. Synthesis and Antiproliferative Effects of [3]Ferrocenophane Transposition Products and Pinacols Obtained from McMurry Cross-Coupling Reactions. Meral Görmen, Pascal Pigeon,Elizabeth A. Hillard, Anne Vessières, Michel Huché, Marie-Aude Richard, Michael J. McGlinchey, Siden Top*, and Gérard Jaouen*. Organometallics, 2012, 31, 5856-5866.
  6. Synthesis, biochemical properties and molecular modelling studies of organometallic SERMs, the ferrocifens and hydroxyferrocifens. Evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormono-independent breast cancer cell lines. S. Top*, A. Vessières, G. Leclercq, J. Quivy, J. Tang, J. Vaissermann, M. Huché, G. Jaouen*. Chem. Eur. J., 2003, 9, 5223-5236.